Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients

被引：18

作者：

Nakamura, Yasuhiro ^{[1
,27
]}

Namikawa, Kenjiro ^{[2
]}

Kiniwa, Yukiko ^{[3
]}

Kato, Hiroshi ^{[4
]}

Yamasaki, Osamu ^{[5
]}

Yoshikawa, Shusuke ^{[6
]}

Maekawa, Takeo ^{[7
]}

Matsushita, Shigeto ^{[8
]}

Takenouchi, Tatsuya ^{[9
]}

Inozume, Takashi ^{[10
]}

Nakai, Yasuo ^{[11
]}

Fukushima, Satoshi ^{[12
]}

Saito, Shintaro ^{[13
]}

Otsuka, Atsushi ^{[14
,15
]}

Fujimoto, Noriki ^{[16
]}

Isei, Taiki ^{[17
]}

Baba, Natsuki ^{[18
]}

Matsuya, Taisuke ^{[19
]}

Tanaka, Ryo ^{[20
]}

Kaneko, Takahide ^{[21
]}

Onishi, Masazumi ^{[22
]}

Kuwatsuka, Yutaka ^{[23
]}

Nagase, Kotaro ^{[24
]}

Onuma, Takehiro ^{[25
]}

Nomura, Motoo ^{[26
]}

Umeda, Yoshiyasu ^{[1
,20
]}

Yamazaki, Naoya ^{[2
]}

机构：

[1] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, Saitama, Japan

[2] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo, Japan

[3] Shinshu Univ, Dept Dermatol, Matsumoto, Japan

[4] Nagoya City Univ, Dept Geriatr & Environm Dermatol, Grad Sch Med Sci, Nagoya, Japan

[5] Okayama Univ, Dept Dermatol, Dent & Pharmaceut Sci, Grad Sch Med, Okayama, Japan

[6] Shizuoka Canc Ctr, Dermatol Div, Shizuoka, Japan

[7] Jichi Med Univ, Dept Dermatol, Tochigi, Japan

[8] Natl Hosp Org, Dept Dermato Oncol Dermatol, Kagoshima Med Ctr, Kagoshima, Japan

[9] Niigata Canc Ctr Hosp, Dept Dermatol, Niigata, Japan

[10] Chiba Univ, Dept Dermatol, Chiba, Japan

[11] Mie Univ, Dept Dermatol, Mie, Japan

[12] Kumamoto Univ, Fac Life Sci, Dept Dermatol & Plast Surg, Kumamoto, Japan

[13] Gunma Univ, Dept Dermatol, Grad Sch Med, Maebashi, Japan

[14] Kyoto Univ, Dept Dermatol, Kyoto, Japan

[15] Kindai Univ Hosp, Dept Dermatol, Osaka, Japan

[16] Shiga Univ Med Sci, Dept Dermatol, Otsu, Japan

[17] Osaka Int Canc Inst, Dept Dermatol Oncol, Osaka, Japan

[18] Univ Fukui, Dept Dermatol, Fukui, Japan

[19] Asahikawa Med Univ, Dept Dermatol, Asahikawa, Japan

[20] Kawasaki Med Sch, Dept Dermatol, Kurashiki, Japan

[21] Juntendo Univ, Dept Dermatol, Urayasu Hosp, Chiba, Japan

[22] Iwate Med Univ, Dept Dermatol, Iwate, Japan

[23] Nagasaki Univ, Dept Dermatol, Nagasaki, Japan

[24] Saga Univ, Fac Med, Dept Internal Med, Div Dermatol, Saga, Japan

[25] Univ Yamanashi, Dept Dermatol, Yamanashi, Japan

[26] Kyoto Univ, Dept Clin Oncol, Kyoto, Japan

[27] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, 1397-1 Yamane, Saitama 3501298, Japan

来源：

EUROPEAN JOURNAL OF CANCER | 2022年 / 176卷

关键词：

CTLA-4; antigen; Immunotherapy; Ipilimumab; Melanoma; Nivolumab; Pembrolizumab; Programmed cell death 1 receptor; Retrospective studies; Japan; SINGLE-ARM; OPEN-LABEL; PD-1; BLOCKADE; PHASE-II; MUCOSAL; IPILIMUMAB; INHIBITORS; NIVOLUMAB; MUTATION; SAFETY;

D O I：

10.1016/j.ejca.2022.08.030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Although anti-PD-1 antibody monotherapy (PD-1) is commonly used to treat advanced acral melanoma (AM), its efficacy is limited. Further, data on the efficacy of PD-1 plus anti-CTLA-4 antibody (PD-1+CTLA-4) for the treatment of AM are limited. Therefore, we compared the efficacy of PD-1+CTLA-4 and PD-1 in the treatment of Japanese patients with advanced AM. Methods: This retrospective study evaluated patients with advanced AM who were treated with PD-1 or PD-1+CTLA-4 as first-line immunotherapy in 24 Japanese institutions between 2014 and 2020. Treatment efficacy focussing on the objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) was compared between the two groups. Results: In total, 254 patients (palm and sole melanoma [PSM], n = 180; nail apparatus melanoma [NAM], n = 74) were included. Among the patients with PSM, the ORR (19% vs. 31%; P = 0.44), PFS (5.9 vs. 3.2 months; P = 0.74), and OS (23.1 vs. not reached; P = 0.55) did not differ significantly between the PD-1 and PD-1+CTLA-4 groups. Among the patients with NAM, the ORR (61% vs. 10%; P < 0.001) was significantly higher and PFS was longer (6.4 vs. 3.8 months; P = 0.10) in the PD-1+CTLA-4 group than in the PD-1 group. Cox multivariate analysis demonstrated that PD-1+CTLA-4 is an independent predictor of a favourable PFS in patients with NAM (P = 0.002). Conclusions: The efficacy of PD-1+CTLA-4 is not superior to that of PD-1 for the treatment of advanced PSM. However, PD-1+CTLA-4 may be more efficacious than PD-1 for the treatment of advanced NAM. (C) 2022 Elsevier Ltd. All rights reserved.

引用

页码：78 / 87

页数：10

共 50 条

[21] Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
Subrahmanyam, Priyanka B.
Dong, Zhiwan
Gusenleitner, Daniel
Giobbie-Hurder, Anita
Severgnini, Mariano
Zhou, Jun
Manos, Michael
Eastman, Lauren M.
Maecker, Holden T.
Hodi, F. Stephen
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[22] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
Bowyer, S.
Prithviraj, P.
Lorigan, P.
Larkin, J.
McArthur, G.
Atkinson, V.
Millward, M.
Khou, M.
Diem, S.
Ramanujam, S.
Kong, B.
Liniker, E.
Guminski, A.
Parente, P.
Andrews, M. C.
Parakh, S.
Cebon, J.
Long, G. V.
Carlino, M. S.
Klein, O.
[J]. BRITISH JOURNAL OF CANCER, 2016, 114 (10) : 1084 - 1089
[23] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
S Bowyer
P Prithviraj
P Lorigan
J Larkin
G McArthur
V Atkinson
M Millward
M Khou
S Diem
S Ramanujam
B Kong
E Liniker
A Guminski
P Parente
M C Andrews
S Parakh
J Cebon
G V Long
M S Carlino
O Klein
[J]. British Journal of Cancer, 2016, 114 : 1084 - 1089
[24] Haemophagocytic lymphohistiocytosis as a complication of combination anti-PD-1 and anti-CTLA-4 checkpoint inhibitor immunotherapy for metastatic melanoma, and the outcome of rechallenge with single-agent anti-PD-1 immunotherapy
Holmes, Zachary
Courtney, Ashling
Hiong, Alison
[J]. BMJ CASE REPORTS, 2022, 15 (08)
[25] Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
Bhave, Prachi
Ahmed, Tasnia
Lo, Serigne N.
Shoushtari, Alexander
Zaremba, Anne
Versluis, Judith M.
Mangana, Joanna
Weichenthal, Michael
Si, Lu
Lesimple, Thierry
Robert, Caroline
Trojanello, Claudia
Wicky, Alexandre
Heywood, Richard
Tran, Lena
Batty, Kathleen
Dimitriou, Florentia
Stansfeld, Anna
Allayous, Clara
Schwarze, Julia K.
Mooradian, Meghan J.
Klein, Oliver
Mehmi, Inderjit
Roberts-Thomson, Rachel
Maurichi, Andrea
Yeoh, Hui-Ling
Khattak, Adnan
Zimmer, Lisa
Blank, Christian U.
Ramelyte, Egle
Kaehler, Katharina C.
Roy, Severine
Ascierto, Paolo A.
Michielin, Olivier
Lorigan, Paul C.
Johnson, Douglas B.
Plummer, Ruth
Lebbe, Celeste
Neyns, Bart
Sullivan, Ryan
Hamid, Omid
Santinami, Mario
McArthur, Grant A.
Haydon, Andrew M.
Long, Georgina, V
Menzies, Alexander M.
Carlino, Matteo S.
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (07)
[26] Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, Celine
Tarhini, Ahmad
Routier, Emilie
Lambotte, Olivier
Ladurie, Francois Leroy
Carbonnel, Franck
Izzeddine, Hassane
Marabelle, Aurelien
Champiat, Stephane
Berdelou, Armandine
Lanoy, Emilie
Texier, Matthieu
Libenciuc, Cristina
Eggermont, Alexander M. M.
Soria, Jean-Charles
Mateus, Christine
Robert, Caroline
[J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (08) : 473 - 486
[27] Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
Afzal, Muhammad Zubair
Mercado, Rima R.
Shirai, Keisuke
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[28] Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
Gauci, Marie-Lea
Boudou, Philippe
Baroudjian, Barouyr
Vidal-Trecan, Tiphaine
Da Meda, Laetitia
Madelaine-Chambrin, Isabelle
Basset-Seguin, Nicole
Bagot, Martine
Pages, Cecile
Mourah, Samia
Resche-Rigon, Matthieu
Pinel, Sylvine
Sassier, Marion
Rouby, Franck
Eftekhari, Pirayeh
Lebbe, Celeste
Gautier, Jean-Francois
[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (08) : 1197 - 1208
[29] Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
Marie-Léa Gauci
Philippe Boudou
Barouyr Baroudjian
Tiphaine Vidal-Trecan
Laetitia Da Meda
Isabelle Madelaine-Chambrin
Nicole Basset-Seguin
Martine Bagot
Cécile Pages
Samia Mourah
Matthieu Resche-Rigon
Sylvine Pinel
Marion Sassier
Franck Rouby
Pirayeh Eftekhari
Céleste Lebbé
Jean-François Gautier
[J]. Cancer Immunology, Immunotherapy, 2018, 67 : 1197 - 1208
[30] Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center
Afzal, Muhammad Z.
Shirai, Keisuke
[J]. MELANOMA RESEARCH, 2018, 28 (04) : 341 - 347

← 1 2 3 4 5 →